Business Wire

OR-NIKE

11.4.2024 20:32:29 CEST | Business Wire | Press release

Share
Nike Kicks Off Multi-Year Innovation Cycle

Today, NIKE, Inc. (NYSE: NKE) extended its position as the undisputed leader of footwear and apparel innovation by debuting a new line-up of products that signaled a multi-year innovation cycle. Brought to life by the full power of digital capabilities and cutting-edge technology, the company is delivering better, faster, more efficient solutions for athletes this summer and opening a world of creative possibilities — including Nike's first sculpted, visible Air Zoom unit in the new Pegasus Premium running shoe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240411422311/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Harnessing its proprietary Air technology, Nike debuts the Nike Pegasus Premium – taking the cushioning that runners love from the iconic Pegasus franchise and adding Nike’s first sculpted, visible Air Zoom unit. The new, sculpted Air Zoom unit is the brand’s biggest Air innovation since the launch of the Nike Air VaporMax. (Photo: Business Wire)

The proprietary, sculpted Air unit connects the heel and forefoot and uniquely contours to the natural profile of the foot, delivering an entirely new springy, smooth sensation. Combined with ZoomX and ReactX foam, the new cushioning system creates more energy return for everyday runners.

In addition, Air, Nike’s most revolutionary, ubiquitous and versatile cushioning platform, powers the products Nike athletes will wear on the track, court and pitch this summer. Nike has optimized Air by leveraging computational design and incomparable athlete data from the Nike Sport Research Lab to create footwear that helps all athletes break barriers.

“For more than 50 years we’ve listened to and over-delivered for our athletes with the best of Nike innovation. We always push the boundaries of what’s possible and take risks to help create the future of sport together,” said John Hoke, Nike’s Chief Innovation Officer. “This summer, the difference maker is the massive energy return that Nike Air delivers to athletes. Taking what we learned from our super-shoe technology, we’re introducing new Nike Air Zoom shapes and sensations across all sports.”

The best of Nike’s Air innovation for this summer will debut in the Nike Blueprint Pack, spanning footwear for track and road racing, basketball, football, skate, breakdancing and lifestyle. The blue, white and orange colorway is a nod to Nike’s co-founder, Bill Bowerman, and his obsession with enabling the best-possible athlete performance.

Nike’s world-class athletes, including Dina Asher-Smith, Shelly-Ann Fraser-Pryce, Eliud Kipchoge and Sha’Carri Richardson, revealed the brand’s 2024 federation kits, which are the most data-driven and visually unified Nike’s ever produced. Based on 4D motion-capture data, with pixel-level precision and specifically designed for each competition, the kits were inspired by the distinct identities and diverse communities of each country and sport.

Nike also revealed A.I.R.Athlete Imagined Revolution. In this co-creation project between elite athletes and Nike designers, Nike used innovative design tools to create the future of Air. The radical concepts are a view into the future of athlete co-creation, as well as the unlimited possibilities of Nike Air.

“There are now no limits to what we can create with Nike Air,” said Hoke. “We’re obsessing new technologies like AI engines and rapid prototyping to continue exploring the unlimited possibilities. Now we can create Nike products with unprecedented fidelity, velocity and impact.”

“We’re thrilled to celebrate another summer of sport with our incredible athletes and the product innovations that will help propel them to achieve their dreams,” said Heidi O’Neill, President, Consumer, Product and Brand, NIKE, Inc. “What you’ll see this year on the pitch, court, road or track signals a new, exciting multi-year cycle of innovation for us. And this summer is just a hint of the game-changing innovations coming across our entire portfolio that will take us into new markets and market share opportunities.”

About NIKE, Inc.

NIKE, Inc., based near Beaverton, Ore., is the world's leading designer, marketer and distributor of authentic athletic footwear, apparel, equipment and accessories for a wide variety of sports and fitness activities. Converse, a wholly owned NIKE, Inc. subsidiary brand, designs, markets and distributes athletic lifestyle footwear, apparel and accessories. For more information, NIKE, Inc.’s earnings releases and other financial information are available on the Internet at http://investors.nike.com. Individuals can also visit http://news.nike.com and follow @NIKE.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240411422311/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types13.7.2026 10:00:00 CEST | Press release

- Treatment with latarcibart led to an 81% median reduction in annualized bleeding rate (ABR) across all bleeding categories and patient types with von Willebrand disease (VWD) - Latarcibart, administered via a once monthly subcutaneous dosing regimen, was shown to be safe and well tolerated over multiple doses in this study - Pivotal Phase 3 VIVID-6 trial evaluating latarcibart’s potential to be the first targeted therapy for VWD is currently enrolling Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for patients with von Willebrand disease (VWD). The data are being shared in an oral presentation today at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH 2026 Congress) in Paris. Latarcibart modulates Protein S to improve hemostasis, potentially enhancing the body’s ability t

Europe’s Demand for Tech Services Accelerates in Q2, As Spending on AI and Managed Services Rises: ISG Index™13.7.2026 10:00:00 CEST | Press release

Combined market up 46%, led by 64% growth in cloud servicesManaged services up 21%, as companies seek cost savings to fund AI Demand for technology services in Europe continued to accelerate in the second quarter, as the region increasingly turns to managed services to reduce costs and cloud services to meet AI objectives, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows second-quarter ACV for the combined market (both managed services and cloud-based as-a-service) soared 46 percent—its largest growth in eight years—to US $13.0 billion. The latest quarter adds to a string of three straight quarters in which growth has averaged 33 percent. “Europe has become the fastest-growing region for technology services, fueled not only by an increasin

Maureen Mahr von Staszewski Joins Heitman European Leadership Team13.7.2026 09:30:00 CEST | Press release

Heitman expands European platform with addition of experienced leader Heitman LLC (“Heitman”), a global real estate investment management firm, today announced the appointment of Maureen Mahr von Staszewski as Managing Director in the firm’s European Real Estate Investment team. As part of Heitman’s European leadership team, Maureen will help drive continued expansion across Europe, supporting the firm’s strategic growth initiatives, capital raising efforts, and investment activity across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713202147/en/ Maureen Mahr von Staszewski Joins Heitman European Leadership Team “We are excited Maureen has joined the Heitman team,” said Caleb Mercer, Managing Director and Head of European Investment at Heitman. “Her breadth and depth of experience in European real estate investment management will help strengthen our innovative and differentiated investment capabilities acro

LTM Partners with Anthropic to Accelerate Claude Adoption and Expand Enterprise Delivery13.7.2026 08:16:00 CEST | Press release

Claude and Claude Code embedded into LTM BlueVerse™ AI Delivery Fabric to power AI-led transformations LTM, the Business Creativity partner to the world's largest enterprises, today announced a partnership with Anthropic, the frontier AI company behind Claude, to accelerate enterprise-scale adoption of Claude, Claude Code and Claude Cowork across engineering, modernization, and business workflows. LTM will combine Claude, Claude Code and Claude Cowork with its enterprise implementation expertise to help clients move from pilots to production with market-leading productivity, throughput, quality underscored by assurance and transparency. LTM will specifically bring this expertise and capability to BFSI, Hi-Tech, Consumer and Production Industry domains. The three strategic focus areas of partnership include:LTM BlueVerse™: AI Delivery Fabric LTM BlueVerse AI Delivery Fabric will serve as the enterprise implementation layer for Claude adoption, integrating Claude and Claude Code into del

Sofinnova Partners Appoints David Evans as Partner13.7.2026 08:00:00 CEST | Press release

Sofinnova strengthens its growth strategy with a high-caliber London-based Partner:Physician-scientist combining frontline clinical experience, health financing and policy expertise, and a proven track record in venture capitalOver 20 years in drug development at Bristol Myers Squibb, Eli Lilly, and the Roche Venture Fund as well as in healthcare policy and financing Sofinnova Partners ("Sofinnova"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, announced the appointment of David Evans as Partner. A physician-scientist with deep pharma and drug development expertise, Evans joins from the Roche Venture Fund, where he most recently served as Senior Investment Director. His career spans frontline patient care as a doctor in Australia and with Médecins Sans Frontières, health policy and financing at the World Bank, and roles across the pharmaceutical industry in health economics & outcomes research and drug development before moving into life-

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye